Department of Public Health, Centre for Health Economic Research (COHERE), University of Southern Denmark, J.B. Winsløwsvej 9B, 5000, Odense C, Denmark.
Hospital Pharmacy, Central Denmark Region, Nørrebrogade 44, 8000, Aarhus C, Denmark.
Appl Health Econ Health Policy. 2018 Feb;16(1):91-106. doi: 10.1007/s40258-017-0360-8.
Automated medication systems have been found to reduce errors in the medication process, but little is known about the cost-effectiveness of such systems. The objective of this study was to perform a model-based indirect cost-effectiveness comparison of three different, real-world automated medication systems compared with current standard practice.
The considered automated medication systems were a patient-specific automated medication system (psAMS), a non-patient-specific automated medication system (npsAMS), and a complex automated medication system (cAMS). The economic evaluation used original effect and cost data from prospective, controlled, before-and-after studies of medication systems implemented at a Danish hematological ward and an acute medical unit. Effectiveness was described as the proportion of clinical and procedural error opportunities that were associated with one or more errors. An error was defined as a deviation from the electronic prescription, from standard hospital policy, or from written procedures. The cost assessment was based on 6-month standardization of observed cost data. The model-based comparative cost-effectiveness analyses were conducted with system-specific assumptions of the effect size and costs in scenarios with consumptions of 15,000, 30,000, and 45,000 doses per 6-month period.
With 30,000 doses the cost-effectiveness model showed that the cost-effectiveness ratio expressed as the cost per avoided clinical error was €24 for the psAMS, €26 for the npsAMS, and €386 for the cAMS. Comparison of the cost-effectiveness of the three systems in relation to different valuations of an avoided error showed that the psAMS was the most cost-effective system regardless of error type or valuation.
The model-based indirect comparison against the conventional practice showed that psAMS and npsAMS were more cost-effective than the cAMS alternative, and that psAMS was more cost-effective than npsAMS.
自动化药物系统已被发现可减少药物处理过程中的错误,但对于此类系统的成本效益知之甚少。本研究的目的是对三种不同的真实世界自动化药物系统与当前标准实践进行基于模型的间接成本效益比较。
所考虑的自动化药物系统为患者特异性自动化药物系统(psAMS)、非患者特异性自动化药物系统(npsAMS)和复杂自动化药物系统(cAMS)。该经济评估使用了在丹麦血液病房和急性医疗单位实施药物系统的前瞻性、对照、前后研究的原始效果和成本数据。有效性用与一个或多个错误相关的临床和程序错误机会的比例来描述。错误被定义为与电子处方、标准医院政策或书面程序的偏差。成本评估基于观察到的成本数据的 6 个月标准化。基于模型的比较成本效益分析是根据效果大小和成本的系统特定假设进行的,在每个 6 个月期间消耗 15,000、30,000 和 45,000 个剂量的情况下进行了情景分析。
在 30,000 个剂量下,成本效益模型表明,以避免临床错误的每单位成本表示的成本效益比为 psAMS 为 24 欧元,npsAMS 为 26 欧元,cAMS 为 386 欧元。比较三种系统在不同错误值下的成本效益关系表明,无论错误类型或评估如何,psAMS 都是最具成本效益的系统。
与常规实践的基于模型的间接比较表明,psAMS 和 npsAMS 比 cAMS 替代品更具成本效益,而 psAMS 比 npsAMS 更具成本效益。